SUBSCRIBE: eNewsletter
A new perspective from a team of Maryland-based cardiovascular clinicians sheds insight on an often forgotten facet of the inherent COVID-19 risk carried by patients with cardiovascular history: the decline in angiotensin-converting enzyme 2 (ACE2) expression associated with aging, and the response of care most common in such patients.
A 40-year-old woman went to the doctor after petechia and palpable purpura appeared on the palms of her hands, fingers, and toes. She appeared chronically ill and had significant weight loss. Her doctor also noted the presences of Osler nodes. She did not have any recent injuries or skin punctures and reported she had been in good health until the last few weeks. Based on these clues, how would you diagnose this patient?
A new study presented at the American College of Cardiology’s Annual Scientific Session Together with World Congress of Cardiology (ACC.20/WCC) has revealed a low birth weight could serve as an indicator for increased risk of cardiovascular disease in mothers.
A new study examining the impact of increased protein intake in older women has returned promising results showing a potential reduction in the risk of one of the most common cardiovascular conditions.
What is the role of ACE inhibition or angiotensin receptor blockers (ARBs) within regard to the novel coronavirus (COVID-19)?
Electronic cigarette use has grown to approximately 1 in every 20 US adults, according to new findings presented virtually at the American College of Cardiology (ACC) 2020 Scientific Sessions this week.
While chemotherapy with anthracycline and trastuzumab have been linked to cardiotoxicity, new research is suggesting a common cardiovascular medication could help offset some of the negative impact on cardiovascular health in breast cancer patients.
While multiple previous studies have detailed the additional risk of arrhythmias associated with patients who have cancer, new data is shedding light on which forms of cancer carry the greatest risk.
In the face of the worldwide coronavirus (COVID-19) pandemic, 4 of the largest cardiology organizations are advising patients receiving treatment with ACE inhibitors (ACE-i) and angiotensin receptor blockers (ARBs) they should not be discontinuing treatment unless it is recommended by their physician.
Until a few weeks ago, telemedicine was primarily seen as a means to improve access to specialty care, reduce healthcare costs and boost patient engagement. And while it has certainly gained traction over the last several years, it still accounted for an extremely small number of total patient encounters, was largely seen as adjunct to traditional in-person clinical care, and restrictions by payers made reimbursements difficult. Combined, these factors largely curtailed the widespread adoption of the virtual practice model. And then came the Coronavirus.
We've noticed that you're using an ad blocker
Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.
